Orexigen Therapeutics, Inc. news

   Watch this stock
Showing stories 1 - 10 of about 77   

Articles published

OREX 7.75 +0.21 (2.79%)
price chart
Leerink: Europe Deal Coming For Orexigen Therapeutics
European approval of Orexigen Therapeutics Inc.'s (NASDAQ: OREX) anti-obesity drug sets the stage for an overseas partnership deal, an analyst said.
News Alerts on Active Notes- Orexigen Therapeutics, Inc. (NASDAQ:OREX ...  StreetWise Report
Investor Alert: Lawsuit against Orexigen Therapeutics, Inc. (NASDAQ:OREX ...  GroundReport
Deadline in Lawsuit for Investors in Orexigen Therapeutics, Inc. OREX Shares ...
On March 3, 2015, in connection with reporting to investors the status of certain patent applications Orexigen Therapeutics, Inc had sought for Contrave, Orexigen Therapeutics, Inc disclosed certain interim results of its ongoing LIGHT study. Shares of ...
Orexigen Therapeutics (OREX) Showing Signs Of A Dead Cat Bounce Today  TheStreet.com
Deadline in Lawsuit for Investors in Orexigen Therapeutics, Inc. (NASDAQ ...  Nasdaq
Orexigen Therapeutics, Inc. -- Stuck Between an Obese Rock and a Hard Place
Get 'em approved and keep selling 'em once they're on the market. Sure, there are details involved in accomplishing each, but from a high-level view, it's that simple.
Orexigen Therapeutics Announces that Tom Cannell has Joined As Chief ...
SAN DIEGO, March 30, 2015 /PRNewswire/ -- Orexigen Therapeutics, Inc. (Nasdaq: OREX) today announced that Tom Cannell has joined as Chief Commercial Officer.
Orexigen Therapeutics, Inc. Rallies As Obesity Drug Mysimba Gets European ...
Orexigen Therapeutics, Inc. (NASDAQ:OREX) announced on Thursday that its weight-loss drug Mysimba (naltrexone HCl / bupropion HCl prolonged release) has been approved by the European Commission to be used in combination with a low-calorie diet ...
OREX Shareholder Alert: Investigation on Behalf of Orexigen Therapeutics ...  MarketWatch
Orexigen Therapeutics, Inc.'s (NASDAQ:OREX) Drug Mysimba, For The ...  WallStreet.org
Analyst: FDA Won't Pull Permit On Orexigen Therapeutics
Orexigen Therapeutics, Inc. (NASDAQ: OREX) sole product, the anti-obesity drug Contrave, almost certainly won't get pulled from the market, an analyst said Friday.
Here's Why Orexigen Therapeutics, Inc. Stock Tumbled 16% In Pre-Market Today  Bidness ETC
Fat Chance: FDA Chastises Orexigen for Disclosing Interim Trial Data  Wall Street Journal (blog)
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of ...
Orexigen Gains Market Share With Contrave Again (OREX)
Sales of the anti-obesity medication Contrave from Orexigen (NASDAQ:OREX) saw a week-over-week improvement of 3.83% this week, with sales just above 11,400, according to industry tracker IMS Health.
Orexigen Therapeutics Embarrasses Arena and VIVUS Again (VVUS, OREX ...  SmallCap Network
Trade-Ideas: Orexigen Therapeutics (OREX) Is Today's "Perilous Reversal" Stock
Orexigen Therapeutics, Inc., a biopharmaceutical company, focuses on the development of pharmaceutical product candidates for the treatment of obesity.
Orexigen Therapeutics (OREX) - Research Analysts' Weekly Ratings Changes  Mideast Time
Stocks in Hot Move: General Electric Company (NYSE:GE), Orexigen ...  eMarketsDaily
Harwood Feffer LLP Announces Investigation of Orexigen Therapeutics, Inc.
NEW YORK, March 11, 2015 /PRNewswire/ -- Harwood Feffer LLP (www.hfesq.com) is investigating potential claims against the board of directors of Orexigen Therapeutics, Inc. ("Orexigen" or the "Company") (NASDAQ: OREX), concerning whether the board ...
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of ...  GlobeNewswire (press release)
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class ...  CNNMoney